In MASLD populations without mandatory T2D, a TriNetX study (n = 6243 per group after PSM) reported a 54% lower 7‐year risk of clinically significant portal hypertension events among GLP‐1 RA users versus non‐users, though the absence of an active comparator and possible unmeasured confounding limits interpretation [31]. The gene discussed is GLP1R; the disease is portal hypertension.